Poster presentations: Treatment
20 Posters
Effects of smoking on lymphocyte subpopulations in patients with MS on dimethyl fumarate
Young Investigator
Maria-Elizabeth Baeva
11
Delayed and recurrent dimethyl fumarate induced-lymphopenia in patients with Multiple Sclerosis.
Young Investigator
Serena Borrelli
09
Rituximab in Multiple Sclerosis: B-lymphocyte population study and its relationship with dosing regimen
Young Investigator
Inês Cunha
71
Assessing the real-world effectiveness of ocrelizumab in patients with multiple sclerosis – CONFIDENCE one-year interim analysis
Young Investigator
Julius Eggebrecht
20
Safety and tolerability in patients with multiple sclerosis receiving ocrelizumab in a real-world setting – CONFIDENCE one-year interim analysis
Young Investigator
Julius Eggebrecht
21
Secondary Autoimmune Diseases following Ocrelizumab Therapy for Multiple Sclerosis
Young Investigator
Sophie Elands
43
Long-term efficacy and safety of ponesimod: Results from randomized phase II core and extension studies in relapsing remitting multiple sclerosis
Mark S. Freedman
37
Therapeutic Plasma Exchange Effect on Neuromyelitis Optica Spectrum Disorder
Young Investigator
Enrique Gomez-Figueroa
58
Propensity-matched comparison of early intensive and escalation treatment strategy in Finnish MS patients
Young Investigator
Katariina Hänninen
16
Effect of oral ponesimod on clinical disease activity and MRI-based outcomes in patients with relapsing multiple sclerosis: Phase 3 OPTIMUM study
Ludwig Kappos
34
Safety and immune cell and immunoglobulin levels with evobrutinib, a Bruton’s tyrosine kinase inhibitor, in relapsing multiple sclerosis: results of an open-label extension to a Phase II study
Xavier Montalban
32
Characteristics of a population-based multiple sclerosis cohort treated with disease-modifying drugs in a universal healthcare setting
Young Investigator
Huah Shin Ng
06
Inhalation of Dimethyl Fumarate encapsulated-nanoparticles attenuates clinical signs and central nervous system inflammation of Experimental Autoimmune Encephalomyelitis animals’ models
Winner Young Investigator Award
Young Investigator
Bárbara Pinto
05
Characterization of cladribine tablets treated MS patients in Finland
Young Investigator
Ilkka Rauma
14
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in DAYBREAK: an open-label extension study of ozanimod phase 1−3 trials
Krzysztof Selmaj
18
Intravenous immunoglobulin for acute attacks in neuromyelitis optica spectrum disorders
Decai Tian
79
Phase I study of ATA188, an off-the-shelf, allogeneic Epstein-Barr virus-targeted T-cell immunotherapy for progressive forms of multiple sclerosis
Jonathan Willmer
27
Real-world demographics, clinical characteristics and treatment patterns in relapsing multiple sclerosis patients on disease-modifying therapy (encore abstract from ACTRIMS/ECTRIMS)
Tjalf Ziemssen
24
Comparative Efficacy of Relapsing Multiple Sclerosis Therapies: A Model-Based Meta-Analysis for Annualized Relapse Rate
Matthew Zierhut
40